Merck (MRK) Stock: Price, Trend, Options & Financials
Merck's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
MRK closed at $152.55 on Aug 21, 2026. The price is +19.2% from its 50-day average and +32.3% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +31.6%, beating SPY by 28.6%. It remains 1.3% below its 52-week high.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
The close is +19.2% from its 50-day average and +32.3% from its 200-day average. Over three months, MRK returned +31.6% versus +3.1% for SPY.
- vs 50-day
- +19.2%
- vs 200-day
- +32.3%
- From 52W high
- -1.3%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
MRK appeared in a UOA top-30 list on 2 of 62 archived scanner sessions: 2 call-side, 0 put-side and 0 on both lists. The latest session did not place it in either top 30. Its larger composite score was 0.48, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-08-19 | #7 | — |
| 2026-06-15 | #16 | — |
Latest chain snapshot
2026-08-21Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.944 calls, 0.067 puts.
Curated-manager ownership
1 of the 20 managers in the project's curated 13F set reported a long Merck position in their latest filing, worth $3M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Baron Capital Group Ron Baron · MRK | $3M | 0.00% | 22,000 | -12.0% reduced | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open MRK Financials →How MRK trades — the working manual
Merck combines a large oncology franchise with vaccines, hospital products and animal health. For the stock, current prescription demand must be weighed against product concentration and exclusivity timelines, while clinical readouts, label expansion and business development determine whether the portfolio can replace mature revenue.
What can move the tape
- 01Prescription volume, market share and new indications across the oncology portfolio.
- 02Clinical-trial results, regulatory decisions and launches from the broader pipeline.
- 03Vaccine demand, hospital-product trends and the stability of animal-health revenue.
- 04Research spending, operating margin, cash generation and business-development returns.
What can fool the read
- 01Dependence on a small number of medicines makes exclusivity and competitive events unusually important.
- 02Clinical or regulatory setbacks can remove expected revenue before replacement products scale.
- 03Drug-pricing policy and payer access can affect realized price as well as prescription volume.
- 04Acquisitions can add pipeline assets while introducing valuation and integration risk.
Merck triggered 2 issuer-level flags in the committed 2026-04-01–2026-08-21 archive. The latest was MRK on 2026-08-19: 3.9× its 30-day average volume while the stock moved +3.6% that session.
Not published yet. The local archive has 1 reported MRK events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-08-23 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-08-21 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-08-21 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-08-21 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-16 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-08-23 | JSON ↓ |
MRK stock questions
Is MRK stock in an uptrend?+
MRK is classified in the “established uptrend” regime as of 2026-08-21: the close is +19.2% from its 50-day average and +32.3% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in MRK mean?+
Merck's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the MRK 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are MRK's income statement and cash flow?+
The dedicated MRK Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no MRK earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.